Naman Ghazal Albar, MD
Internal Medicine · Webster Groves, MONPI 1639144785
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,750 of the $21,005 with a category attached, or 65.5%. Johnson & Johnson accounts for 73.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $13,971 and has fallen 94.3% since, to $796 in 2025. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $88.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$15K
- Abbott$2K
- AstraZeneca$968
- Novo Nordisk$781
- Sequel Med Tech, LLC$418
- Sanofi-aventis U.S. LLC$275
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$13,75065%
- Travel & lodging$1,1936%
- Food & beverage$6,03729%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 51 | $15,450 |
| Abbott | 37 | $1,957 |
| AstraZeneca(2 entities) | 42 | $968 |
| Novo Nordisk | 34 | $781 |
| Sequel Med Tech, LLC | 4 | $418 |
| Sanofi-aventis U.S. LLC | 15 | $275 |
| Medtronic(2 entities) | 7 | $161 |
| Boehringer Ingelheim | 2 | $144 |
| Amarin Pharma, Inc. | 7 | $102 |
| Tandem Diabetes Care, Inc. | 6 | $88 |
| AbbVie | 4 | $70 |
| Merck | 4 | $68 |
| Lilly USA, LLC | 3 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $51 |
| Dexcom, Inc. | 2 | $49 |
| Clarus Therapeutics Inc. | 2 | $46 |
| Pfizer | 2 | $46 |
| Averitas Pharma Inc. | 2 | $33 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Bayer | 1 | $25 |
| Globus Medical | 1 | $23 |
| Amgen | 1 | $22 |
| Insulet Corporation | 1 | $22 |
| Aegerion Pharmaceuticals, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$14,751
- FreeStyle Libre 2$794
- FREESTYLE LIBRE 3$580
- TWIIST$391
- JARDIANCE$125
- Ozempic$124
- RYBELSUS$122
- BREZTRI$112
- FreeStyle Libre$112
How this compares
$21,005 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 205 | $285,821 |
| FarxigaDapagliflozin Propanediol | 192 | $176,904 |
| TrulicityDulaglutide | 112 | $158,599 |
| MounjaroTirzepatide | 86 | $134,734 |
| JardianceEmpagliflozin | 79 | $102,610 |
| InvokanaCanagliflozin | 48 | $55,068 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $50,875 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $44,514 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $39,724 |
| Humalog Kwikpen U-100Insulin Lispro | 95 | $37,095 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $32,732 |
| JanuviaSitagliptin Phosphate | 15 | $24,435 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $22,350 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $20,677 |
| Bydureon BciseExenatide Microspheres | 25 | $19,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $67 | $293,334198 claims |
| Novo NordiskOzempic | $781 | $285,821205 claims |
| AstraZenecaFarxiga | $968 | $176,904192 claims |
| Boehringer IngelheimJardiance | $144 | $102,61079 claims |
| Johnson & JohnsonInvokana | $15,450 | $55,06848 claims |
| MerckJanuvia | $68 | $24,43515 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $275 | $22,35026 claims |
| AbbVieSynthroid | $70 | $1,39125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Webster Groves
- Timothy SmithSaint Peters$428K
- Craig DietzKansas City$226K
- Kevin SuttmoellerKansas City$198K
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Dima DandachiColumbia$157K
- Justin SteinkampSaint Charles$139K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.